In the endpoint adjudication space the gold standard for the review of clinical outcomes is to have standardized universal event definitions. Although there have been multiple global kidney outcome trials in the past 10 years, there is currently no such universal definition for End Stage Kidney Disease. In addition to this, the adjudication of kidney endpoints still faces many clinical, practical and regional challenges. In this interactive webinar, our CMO Dr. Maria Ali will discuss this topic with leading nephrologists Prof. Dan Weiner and Prof. Stephen Seliger to gather their perspectives on these issues and the latest thinking on approaches to address them.
What you will learn:
We hope you to see you there.
The session will be streamed live on: September 3 at 11:00 am USA EST
Maria serves as the Chief Medical Officer for George Clinical, responsible for continuing to build the organization’s enviable network of investigators and scientific leaders. Previously, she led the medical and safety services group at George Clinical who provide safety management, endpoint adjudication, medical monitoring and scientific leadership for both commercially sponsored and academic clinical trials. Maria has worked closely with the scientific leads at the George Institute to develop and implement scientific leadership models for George Clinical studies, as well as to develop new ideas for clinical research, and processes to improve clinical trial design and efficiencies. Maria has several years’ experience in both public health and clinical research as well as research management across a range of settings including hospitals, academic and clinical research organizations.
Dr. Stephen Seliger received his medical education from New York University School of Medicine and his Master’s of Science in Epidemiology from the University Of Washington School Of Public Health. He is an Associate Professor in the Department of Medicine, Division of Nephrology at the University of Maryland School of Medicine. His research interests relate to Cognitive and Physical Function in older adults with Chronic Kidney Disease, Cardiac-specific biomarkers in aging patients, and Polycystic Kidney Disease. He is a member of the editorial board for Circulation, and is the Associate Editor of the Clinical Journal of the American Society of Nephrology (CJASN). He also serves as Chairman of the Board of Directors for ESRD Network 5. He has also served on many of George Clinical’s Endpoint Adjudication Committees as adjudicator and Co-Chair.
Dr. Daniel Weiner is a graduate of Tufts University School of Medicine has completed a Masters Degree Program in Clinical Care Research at the Graduate School of Biomedical Sciences. He is a nephrologist at Tufts Medical Center and an Associate Professor of Medicine at Tufts University School of Medicine. His research interests focus on the intersection of cardiovascular disease and kidney disease. His work includes evaluating decision-making in advanced kidney diseases and cognitive function in people with chronic kidney disease. Dr. Weiner also conducts research in the dialysis population, examining dialysis practices, and he is the national principal investigator for a large pragmatic clinical trial evaluating nutritional supplements in haemodialysis patients with Dialysis Clinic, Inc., where he is the Medical Director of Clinical Research. He has represented the American Society of Nephrology as a leader on their policy committees, he was the deputy editor of the American Journal of Kidney Diseases, and he is the editor-in-chief of Kidney Medicine and the Primer on Kidney Diseases. He serves on George Clinical’s studies in the capacity of Endpoint Adjudication Committee Co-Chair and adjudicator.
Meet with George Clinical! Contact us to schedule a time now.